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Abstract
Background: A common feature of Alzheimer's disease (AD) pathology is the abundance of
activated microglia in neuritic plaques containing amyloid-beta protein (Aβ) and associated
molecules including heparan sulfate proteoglycan (HSPG). Besides the role as pathological
chaperone favouring amyloidogenesis, little is known about whether or not HSPG can induce
microglial activation. Cultures of primary murine microglia were used to assess the effect of HSPG
on production of proinflammatory molecules that are known to be present in neuritic plaques of
AD.
Results: HSPG stimulated up-regulation of tumor necrosis factor-alpha (TNF-α), production of
inducible nitric oxide synthase (iNOS) mRNA and accumulation of TNF-α protein and nitrite
(NO2
-) in a time- and concentration-dependent manner. The effects of HSPG were primarily due
to the property of the protein core as indicated by the lack of microglial accumulation of TNF-α
and NO2
- in response to denaturated HSPG or heparan sulfate GAG chains (HS).
Conclusion: These data demonstrate that HSPG may contribute to chronic microglial activation
and neurodegeneration seen in neuritic plaques of AD.
Introduction
Senile plaques in the Alzheimer disease (AD) brain are
characterized by the presence of an amyloid core consist-
ing of fibrillar Aβ, surrounded by a wreath of dystrophic
neurites and activated microglial cells. Reactive microglia
release a variety of potentially neurotoxic compounds,
including cytokines and free radicals. Many research
groups have provided evidence that deposition of aggre-
gated Aβ is centrally involved in the chronic inflammatory
process occurring in senile plaques of AD brain [1,2].
Aβ is a 39- to 42-amino-acid peptide that arises from pro-
teolytic processing of the amyloid precursor protein (APP)
[3,4]. The Aβ peptide that is found in the senile plaques
and cerebrovascular deposits exists as a multimeric aggre-
gate with a fibrillar appearance [5]. Several other mole-
cules have also been shown to be associated with Aβ
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deposits, and in vitro studies of fibrillogenesis suggest
they may be important in the aggregation and persistence
of the Aβ fibrils in vivo. These include apolipoprotein E,
laminin, acetylcholinesterase, α1-antichymotrypsin and
heparan sulfate proteoglycan (HSPG) [6-11].
HSPG is a multifunctional macromolecule characterized
by a core polypeptide to which glycosaminoglycans
(GAGs) are covalently attached. There are at least four dif-
ferent classes of HSPG present in AD, which are either
associated with the cell membrane or with the extracellu-
lar matrix [12]. HSPG has been consistently associated
with both diffuse and neuritic plaques [13,14]. Its early
presence in AD pathological alterations as well as its
immunohistochemical colocalization with all varieties of
Aβ plaques, irrespective of their stage of maturation, have
suggested that HSPG could play an active role in plaque
formation. In this regard it has been proposed that HSPG
facilitates Aβ deposition and/or promotes Aβ persistence
by inhibiting clearance mechanisms, thus augmenting the
formation of Aβ deposits in AD [15]. Consistent with this
hypothesis, in vitro studies have shown that HSPG can
bind with high affinity to Aβ as well as to APP and it pro-
tects Aβ from protease degradation [16-19].
Besides its function in amyloidogenic pathways, HSPG
might contribute to AD pathogenesis also through activa-
tion of microglial cells. This possibility has never been
investigated. To study this we have assessed in "in vitro"
cultures of mouse microglial cells, two known markers of
their activation, i.e. production of the proinflammatory
cytokine tumor necrosis factor-α (TNF-α) and expression
of the mRNA for the inducible nitric oxide (NO) synthase
(iNOS). This enzyme is generated in microglia in response
to a variety of pro-inflammatory cytokines and bacterial
products, such as lipopolysaccharide (LPS). In addition,
we have measured in the culture media supernatants the
accumulation of NO2
-, a good proxy for generation of NO
by iNOS. Our results show that HSPG might contribute to
neurodegeneration in neuritic plaques of AD also through
activation of microglial cells and the ensuing increased
inflammatory response.
Materials and methods
Reagents
Heparan sulfate proteoglycan (HSPG), heparan sulfate
(HS), lipopolysaccharide (LPS, from Escherichia coli
026.B6) were purchased from Sigma (St Louis, MO, USA)
and dissolved in clinical pyrogen-free H2O. Levels of
endotoxin in HSPG and HS stocks were measured by E-
TOXATE (Limulus Amebocyte Lysate, LAL) kit purchased
from Sigma (St Louis, MO, USA).
Preparation of Microglial Cultures
Mice were obtained from Charles River Laboratories, Inc.
(Wilmington, MA, USA) and were used according to insti-
tutional guidelines that are in compliance with national
(D.I. no. 116, G.U. suppl. 40, Feb. 18, 1992, Circolare
No.8, G.U., 14 Luglio 1994) and international law and
policies (EEC Council Directive 86/609, OJ L358, 1 Dec.
12, 1987; Guide for the Care and Use of Laboratory Ani-
mals, U.S. National Research Council, 1996). Primary
murine microglial cultures were prepared as previously
described [20]. Briefly, cerebral cortical cells from day 1-
old mice were dissociated with 0.25% trypsin and 0.1%
DNAse (Sigma) and plated in 75 cm2 culture flasks (Corn-
ing, Acton, MA) in Dulbecco's Modified Eagle's Medium
(DMEM) (Invitrogen Corporation Grand Island, NY,
USA) containing 10% heat-inactivated FBS (Invitrogen
Corporation Grand Island, NY, USA) and 100 µg/ml gen-
tamicin (Invitrogen Corporation Grand Island, NY, USA).
Dissociated glial cultures were maintained at 37°C with
5% CO2 and medium was replenished 4 days after plating.
On day twelve of culture, flasks were shaken for 2 hours.
The culture media supernatants (containing predomi-
nantly microglia and oligodendrocytes) were then col-
lected and the cells were plated in either 96-well tissue
plates (Nunc, Roskild, DK) at a concentration of 4 × 104
cells per 100 µl per well, or in 48-well tissue plates at a
concentration of 25 × 104 per 500 µl per well, and main-
tained at 37°C with 5% CO2 for 1 hour. Loosely adherent
oligodendrocytes were then removed from the cultures by
gentle shaking of the culture plates by hand. After pouring
off the culture media supernatants (containing oli-
godendrocytes), the adherent microglia were maintained
at 37°C with 5% CO2 for subsequent treatment. The
purity of microglial cultures was routinely assessed by
staining with the F4/80-antibody (Serotec, Oxford, UK),
which recognizes a glycoprotein expressed predominantly
in microglia/macrophages cells [21], and found to be in
the range of 96–98% in all cell preparations.
Exposure of microglia to HSPG
Microglial cells were incubated with HSPG at a concentra-
tion of 5, 15, 30, 40 µg/ml for 2, 4, 12, 24 and 48 h. After
the indicated times, culture supernatants were harvested,
and frozen at -70°C until assayed for levels of secreted
TNF-α and nitrite (NO2
-). After 4 h total RNA for each
conditions was isolated from cells plated in 48-well tissue
culture plates, using the TRIzol reagent protocol (Invitro-
gen; Carlsbad, CA, USA). In some experiments cells were
exposed to 15 µg/ml of HS or HSPG denaturated at 90°C
for 10 min. After treatment at indicated times, culture
media supernatants were assayed for NO2
- accumulation
and TNF-α release as described below.Immunity & Ageing 2005, 2:11 http://www.immunityageing.com/content/2/1/11
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TNF-α assay
Antigenic mouse TNF-α was detected by ELISA system
from Biosurce (Camarillo, CA, USA), and based on the
quantitative "sandwich" enzyme immunoassay tech-
nique. The sensitivity of the assay was 10 pg/ml.
Nitrite assay
Nitrite (NO2
-) is a stable end-product used extensively as
an indicator of NO production by cultured cells. In our
experimental conditions, NO2
- accumulation was assayed
by the Griess reaction, according to the method previously
described [22]. Briefly, culture media supernatants were
mixed with equal amounts of Griess reagent (p-ami-
nobenzene sulfonamide 1%, naphtylethylenediamide
0.1% in phosphoric acid 2.5%) in 96-well plates: samples
were incubated at room temperature for 10 min, and sub-
sequently absorbance was read at 540 nm using a micro-
plate reader. NO2
-  concentrations were calculated in
accordance with a sodium nitrite standard curve.
RT-PCR
One µg total RNA quantitated spectrophotometrically and
isolated from each condition was reverse transcribed
using oligo(dT)20-primers and Superscript II-Reverse
Transcriptase according to the manifacturer's protocol
(Invitrogen, Carlsbad, CA, USA). c-DNA equivalent to 20
ng of total RNA was subjected to subsequent PCR analysis
in a total volume of 30 µl containing 25 pmol of primers
specific for TNF-α, iNOS and glyceraldehyde phosphate
dehydrogenase (GAPDH; used as an internal control)
(Table I), 10 mM Tris-HCl pH 8.3 (at 25°C), 50 mM KCl,
10% DMSO, 1.25 mM MgCl2, 250 µM each of dATP,
dCTP, dGTP, dTTP, and 1.5 units AmpliTaq DNA-
polymerase (Roche, Branchburg, NJ, USA). PCR was per-
formed at the following conditions: (1) 2 min at 93°C;
(2) 30 sec at 93°C, 30 sec at 60°C (TNF-α) or at 68°C
(iNOS and GAPDH), 45 sec at 72°C for 26 cycles (iNOS),
24 cycles (TNF-α) or 20 cycles (GAPDH); (3) 10 min. at
72°C. PCR products were analysed on 1.5% agarose gel
containing 10 µg/ml ethidium bromide. Controls
included RNA subjected to the RT-PCR procedure without
addition of reverse transcriptase and PCR performed in
the absence of c-DNA which always yelded negative
results.
Statistical analysis
Data are expressed as means ± standard deviations (SD).
Statistical evaluation was performed by repeated measures
ANOVA (analysis of variance) followed by Dunnet's test
for specific comparisons. Statistical significance was set at
P < 0.05.
Results
1. HSPG triggers production of NO2
- and TNF-α in cultured 
microglia
To test whether the interaction of HSPG with microglia
could induce the production of proinflammatory and
potentially cytotoxic mediators, we assayed the accumula-
tion of NO2
- as an indirect measure of NO production
from mouse primary microglia stimulated with HSPG
and, for comparison, with LPS. As shown in Fig. 1, micro-
glia in resting conditions did not release detectable NO2
-
even after a 48-h incubation, whereas HSPG induced sig-
nificant accumulation of NO2
-  in culture media
supernatants in the range of that observed with LPS. The
effect of HSPG on NO2
- production was time and concen-
tration-dependent, with maximal accumulation observed
at 48 h (7.5. ± 0.5-fold increase over control at 30 µg/ml
HSPG; P < 0.05, n = 9) (Fig. 1A) and production already
significantly increased after a 24 h exposure to 15 µg/ml
(5.2 ± 0.4-fold increase over control; P < 0.05, n = 9) (Fig.
1B). We also investigated whether or not HSPG was able
to induce the production of TNF-α by microglia.
Untreated cells constitutively produced very small
amounts of TNF-α, whereas their stimulation with HSPG
or LPS resulted in the release of significant levels of TNF-
α, with maximal accumulation observed at 4 h (25 ± 1.8-
fold increase over control; P < 0.05, n = 9), followed by a
decrease at later times (Fig. 2A). Concentration-response
studies demonstrated that the amount of TNF-α released
into the culture media supernatants increased with
increasing concentrations of HSPG (Fig. 2B). TNF-α
release was already significantly increased after a 24 h
exposure to 15 µg/ml HSPG (11.6 ± 0.85.-fold increase
over control; P < 0.05, n = 9). Specificity of the effects of
Table I: Oligonucleotide Primers Used for cDNA amplification
Probe Cycles Orientation Tann Sequence Length of PCR Fragments (bp)
GAPDH 20 sense
antisense
68 5'TGAAGGTCGGTGTGAACGGATTTGGC3'
5'CATGTAGGCCATGAGGTCCACCAC3'
983
iNOS 26 sense
antisense
68 5'CCCTTCCGAAGTTTCTGGCAGCAGC3'
5'GGCTGTCAGAGCCTCGTGGCTTTGG3'
493
TNFα 24 sense
antisense
60 5'TTCTGTCTACTGAACTTCGGGTGATCGGTCC3'
5'GTATGAGATAGCAAATCGGCTGACGGTGTGGG3'
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Effect of HSPG on the accumulation of NO2
- from murine  microglia Figure 1
Effect of HSPG on the accumulation of NO2
- from 
murine microglia. In panel A, time course of NO2
- pro-
duction by murine microglia in response to HSPG. Microglial 
cells were cultured in 96-well plates and stimulated with 30 
µg/ml HSPG for up to 48 h. In panel B, dose-dependent 
effect of HSPG on the accumulation of NO2
- by murine 
microglia. Microglial cells were cultured in 96-well plates and 
stimulated for 24 h with increasing concentrations of HSPG, 
or 100 ng/ml LPS. Mean values ± SD of assays performed 
with culture media supernatants collected and pooled from 
triplicate wells for each condition are shown (n = 9). Both 
panels depict a representative experiment out of three per-
formed with similar results. **p < 0.01.
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Effect of HSPG on TNF-α release by murine microglia Figure 2
Effect of HSPG on TNF-α release by murine micro-
glia. In panel A, time course of TNF-α production by 
murine microglia in response to HSPG. Microglial cells were 
cultured in 96-well plates and stimulated with 30 µg/ml HSPG 
for up to 24 h. In panel B, dose-dependent effect of HSPG 
on the accumulation of TNF-α by murine microglia. Micro-
glial cells were cultured in 96-well plates and stimulated for 
24 h with increasing concentrations of HSPG or 100 ng/ml 
LPS. Mean values ± SD of assays performed with culture 
media supernatants collected and pooled from triplicate 
wells for each condition are shown (n = 9). Both panels 
depict a representative experiment out of three performed 
with similar results. **p < 0.01.
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HSPG on microglial activation was confirmed by LAL test
that excluded trace levels of endotoxin in our HSPG
stocks.
2. HSPG induces expression of iNOS and TNF-α mRNA in 
cultured microglia
To determine whether the production of NO2
- and TNF-α
triggered by HSPG reflected induction of iNOS and TNF-
α mRNA, RT-PCR analysis was performed on microglia
total RNA, using probes complementary to the mouse
macrophage iNOS and TNF-α coding sequences. In rest-
ing conditions the mRNA expression for iNOS and TNF-α
in microglia was absent. On the contrary, mRNA levels for
iNOS and TNF-α were clearly induced after stimulation of
the cells for 4 h with HSPG at the concentration of 15 µg/
ml or 100 ng/ml LPS (Fig. 3).
3. Microglial activation induced by HSPG is mediated 
primarily by the protein core
To examine whether the protein core or the GAGs of
HSPG were involved in mediating microglial activation,
the effects of HSPG were compared with those obtained
using HSPG denaturated at 90°C for 10 min (HSPG-hd)
or HS-GAG chains (HS). As shown in Fig. 4, exposure of
microglia to 30 µg/ml HSPG-hd almost completely abol-
ished the production of NO2
- (1 ± 0.2 µM; P < 0.05, n = 9)
and particularly of TNF-α (98 ± 10 pg/ml; n = 9). Stimu-
lation with 30 µg/ml HS only slightly affected release of
TNF-α (200 ± 18 pg/ml; P < 0.05, n = 9) but not
Effect of HSPG on iNOS and TNF-α mRNA expression in murine microglia Figure 3
Effect of HSPG on iNOS and TNF-α mRNA expression in murine microglia. One-day-old microglial cells were cul-
tured in 48-well plates and then stimulated for 4 hours with 15 µg/ml HSPG or 100 ng/ml LPS. Total RNA was extracted and 
analysed by RT-PCR. The densitometric evaluation of the bands obtained from three independent experiments in duplicates 
are reported (n = 6); values are expressed as the relative level of iNOS/GAPDH and TNFα/GAPDH. *p < 0.05.
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accumulation of NO2
- (0.8 ± 0.1 µM; n = 9). The lack of
ability of HSPG-hd and HS to maintain NO2
- accumula-
tion and TNF-α release appeared to be mediated at the
transcriptional level since HSPG-hd and HS failed to
increase both iNOS and TNF-α mRNA transcription (Fig.
5).
Discussion
The identification in senile plaques of pathologic stimuli
that can lead to microglial activation represents one of the
important issues of immunologic research in AD. Previ-
ous studies have shown that microglia upon stimulation
with Aβ can produce proinflammatory and cytotoxic
mediators, and that these mediators play a role in the
pathogenesis of AD [23-26]. The demonstration of the
indirect neuronal injury prompted us to investigate if, in
addition to Aβ, others molecules present in senile plaques
could be involved in similar mechanisms of microglial
activation. We have identified HSPG as a potential candi-
date in this process on the basis that this molecule has
been found to be associated with Aβ peptide-containing
deposits and suggested to act as pathological chaperone,
increasing β-pleated structure within Aβ [27,28].
We demonstrate that HSPG is able to induce the release of
NO2
- and TNF-α by cultured primary murine microglia.
By assessing iNOS and TNF-α mRNA expression with RT-
PCR we have also shown that the release of NO and TNF-
α in HSPG-stimulated microglial cells is due to the induc-
tion of iNOS and TNF-α gene expression. These findings
suggest that, in addition to Aβ, also HSPG is able to acti-
vate microglia with production of proinflammatory mol-
ecules known to be present in the brain of AD patients.
The precise mechanism by which microglia mediate neu-
ronal cell injury in AD is incompletely understood and
several mediators have been proposed, among them NO
and TNF-α [29-31]. Even though physiological levels of
NO may influence synaptic efficacy by regulating
neurotrasmitter release [32], excess NO may cause neuro-
nal degeneration by combining with oxygen radicals such
as superoxide anion to form the highly toxic peroxynitrite
ion [33]. Similarly, TNF-α has been reported to be trophic
to rat hippocampal neurons [34]. However, transgenic
mice that overexpress TNF-α exibit severe inflammation
and neurodegeneration [35]. Moreover, in vitro studies
have shown that some Aβ-induced microglial activities,
including neurotoxicity and chemokine production, are
mediated through release of endogenous TNF-α
[23,36,37]. That TNF-α is presumably involved in AD
pathology is also supported by its elevated levels in the
serum, CSF and cerebral cortex of AD patients [38,39]. In
view of the information summarized above, it is conceiv-
able that generation of NO and TNF-α from microglial
cells is one means by which HSPG may enhance the
inflammatory reaction in neuritic plaques, and thus
pathogenesis of AD. However, it must be pointed out that
astrocytes represent the main source of NO in the plaques
Effect of heat denaturated HSPG and HS-GAG chains on  NO2
- and TNF-α release by murine microglia Figure 4
Effect of heat denaturated HSPG and HS-GAG 
chains on NO2
- and TNF-α release by murine micro-
glia. Microglial cells were cultured in 96-well plates and stim-
ulated with 15 µg/ml HSPG, 15 µg/ml heat denaturated 
HSPG (HSPG-hd) or 15 µg/ml HS-GAG chains (HS). After 24 
h, culture media supernatants were assayed for NO2
- accu-
mulation (A) and TNF-α release (B). Mean values ± SD of 
assays performed with culture media supernatants collected 
and pooled from triplicate wells for each condition are 
shown (n = 9). Both panels depict a representative experi-
ment out of three performed with similar results. *p < 0.05, 
**p < 0.01.
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whereas release of neurotoxic levels of NO by microglia
has been shown in vitro [40,23,24,41]. Future studies will
be needed in order to determine whether HSPG also acti-
vates astrocytes to produce NO and TNF-α.
The lack of inflammation and microglial activation
described in diffuse plaques opens the question about the
actual proinflammatory role played by HSPG at early
stages of plaque evolution. Our results show that activa-
tion of microglial cells by HSPG is concentration-depend-
ent, both in terms of NO2
-  accumulation and TNF-α
release in the culture medium, and that 15 µg/ml of the
compound is sufficient to trigger the activation process.
Although HSPG has been immunohistologically localized
to senile plaques its biochemical isolation from these
structures, and thus its quantification, have yet to be per-
formed [42]. Thus, we cannot establish at present whether
the threshold for microglial activation we found can
Effect of heat denaturated HSPG and HS-GAG chains on iNOS and TNF-α mRNA expression in murine microglia Figure 5
Effect of heat denaturated HSPG and HS-GAG chains on iNOS and TNF-α mRNA expression in murine 
microglia. Microglial cells were cultured in 48-well plates and then stimulated for 4 hours with 15 µg/ml HSPG, 15 µg/ml heat 
denaturated HSPG (HSPG-hd), 15 µg/ml HS-GAG chains (HS) or 100 ng/ml LPS. Total RNA was extracted and analysed by RT-
PCR. The densitometric evaluation of the bands obtained from three independent experiments in duplicates are reported (n = 
6); values are expressed as the relative level of iNOS/GAPDH and TNF-α/GAPDH. *p < 0.05.
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explain the discrepancies in immunohistochemical local-
ization of HSPG in diffuse plaques lacking inflammation.
The cellular source of HSPG in mammalian brain is repre-
sented by microglia and astrocytes which have been
shown by immunofluorescence and/or western blotting
to express HSPG both in vitro and in vivo [43,44]. Never-
theless, the factors implicated in HSPG biosynthesis and
deposition have been poorly investigated. Recently regu-
lation of HSPG by injury and IL-1α has been demon-
strated in astrocytes and microglia [45]. Therefore, the
stimulation of microglial cells by HSPG, followed by
increased production of proinflammatory cytokines could
stimulate further HSPG formation in an autocrine, feed-
forward manner.
The importance of HSPG deposition in AD pathogenesis
is supported by the fact that HSPG binds Aβ, accelerates
Aβ fibril formation and maintains Aβ fibril stability [46].
Most of these effects of HSPG have been shown to be due
to its associated HSGAG side-chains, as also suggested by
the lack of extracellular Aβ deposits in transgenic mice
overexpressing HSPG protein core [47]. This contrasts
with our results showing that the proinflammatory role of
HSPG is primarily mediated by its protein core. However,
in these transgenic mice HSPG was detected only inside
the cells, i.e. without accumulation of the compound in
the extracellular environment, which instead is a hallmark
of AD neurodegeneration. Studies in these animals, there-
fore, do not allow drawing conclusions about the role of
extracellular HSPG in AD.
In conclusion, the potential participation of HSPG in NO
and TNF-α-mediated neuronal injury induced by micro-
glia adds a novel biological role of this molecule in the
pathogenesis of AD. These data indicate that HSPG plays
an immunomodulatory role in the activation of micro-
glia, in addition to that proposed in amyloidogenic
pathways and demonstrate another mechanism by which
immune responses may be triggered in AD brain. There-
fore, a further understanding of the role of HSPG in the
pathogenesis of AD would assist in the development of
rational, targeted therapeutic strategies to combat this
neurodegenerative disorder.
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